Home >> Top News >> Qiagen broadens GeneReader applications

Qiagen broadens GeneReader applications

Print Friendly, PDF & Email

July 27, 2018Qiagen has introduced next-generation sequencing solutions for a range of hereditary diseases on its GeneReader NGS System. The customizable QIAact target enrichment panels enable the analysis of more than 13 hereditary disease groups, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, and universal carrier screening. The solutions integrate the company’s QCI analysis, which includes the Human Gene Mutation Database, a knowledge base containing comprehensive data on inherited disease mutations for genetic and genomic research.

“Genetic laboratories are eager to gain deeper insights into a range of hereditary diseases by using the power of NGS technology but have been held back by the lack of complete workflows and powerful bioinformatics solutions,” Peer M. Schatz, CEO of Qiagen, said in a press release. “We are pleased to offer the first complete Sample to Insight solution for analysis of hereditary diseases. Our solution, anchored by the GeneReader NGS System, provides the complete solution that labs need to efficiently and reliably perform genetic analysis.”

More top news

x

Check Also

Therascreen EGFR RGQ PCR kit approved as CDx

Oct. 1, 2018—Qiagen announced that the FDA has approved a PMA supplement expanding the labeling claim of the Therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s Vizimpro (dacomitinib) for first-line treatment of patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or an exon 21 L858R mutation.

X